During 2004-05, the double blind placebo control trial conducted in previous years was un-blinded and 29 new number of symptom were observed in respect of Terminalia arjuna. The details were placed in the Scientific Advisory Committee and General Body for deliberations.
A KAPB survey was conducted through a questionnaire. It was an anonymous, unlinked & confidential survey. The conclusions were:
- Even though majority of respondents were aware of the concept of drug proving, their current knowledge regarding the same appears to be inadequate and not updated.
- Majority of respondents were not aware of any drug proving programmes conducted in NHMC.
- It was interesting to note that majority of respondents were having fear of developing severe symptoms during drug proving, without even participating in drug proving. This was due to inadequate knowledge or misconceptions regarding drug proving.
- It was indeed happy to note that majority of respondents believed in the concept of drug proving.
- Majority of respondents had never participated in any drug proving programme.
- It could be observed that majority of respondents considered drug proving essential, ethical and feasible, even though actual participation in drug proving is negligible.
- The fact that drug proving requires only a relatively healthy state, was not known to majority of respondents, who believed that a totally healthy state was necessary.
- More than half of the respondents believed that only potentized drugs could be used in drug proving.
- Majority were unaware that drug proving can be beneficial and can improve health after proving.
- It was observed that more than half of the respondents, showed genuine interest in participating in future drug proving programmes. The remaining half who lacked adequate knowledge about drug proving, had effectively motivated, for voluntary pariticipation in future programmes.